2018
2 PFO closure is superior to medical therapy for cryptogenic stroke: a meta-analysis of randomised controlled trials
Ahmad Y, Howard J, Arnold A, Shun-Shin M, Cook C, Malik I, Mayet J, Francis D, Sen S. 2 PFO closure is superior to medical therapy for cryptogenic stroke: a meta-analysis of randomised controlled trials. Heart 2018, 104: a2. DOI: 10.1136/heartjnl-2018-bcs.2.Peer-Reviewed Original ResearchMedical therapyCryptogenic strokeDevice closureAtrial fibrillationRecurrent strokePFO closureNew-onset atrial fibrillationRisk of AFOnset atrial fibrillationPrimary safety endpointPrimary efficacy endpointPrevention of strokeEfficacy endpointFurther strokeSafety endpointTreat basisPatent foramenPatientsTherapyStrokePFOTrialsEndpointPreventionClosure
2013
Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review Of Cardiovascular Therapy 2013, 11: 1029-1049. PMID: 23984927, DOI: 10.1586/14779072.2013.815423.Peer-Reviewed Original ResearchConceptsStroke preventionAntithrombotic therapyAntithrombotic agentsNovel oral anticoagulation agentsAtrial fibrillation guidelinesOral anticoagulation agentsDrug-drug interactionsDirect antidoteAF patientsAnticoagulation monitoringAnticoagulation agentsAtrial fibrillationAbsolute riskAntithrombotic pharmacotherapyRelative riskLower riskStrong recommendationsPatientsThromboembolismPreventionRiskTherapyInherent risksAuthors' knowledgeAgents
2012
Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance
Ahmad Y, Lip GY. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance. Heart 2012, 98: 1404. PMID: 22698856, DOI: 10.1136/heartjnl-2012-302101.Peer-Reviewed Original ResearchStroke Prevention in Atrial Fibrillation: Where are We Now?
Ahmad Y, Lip GY. Stroke Prevention in Atrial Fibrillation: Where are We Now? Clinical Medicine Insights Cardiology 2012, 6: cmc.s8976. PMID: 22408371, PMCID: PMC3296491, DOI: 10.4137/cmc.s8976.Peer-Reviewed Original ResearchStroke preventionAtrial fibrillationOnly successful therapyLow-risk patientsBetter risk stratificationStroke prophylaxisRisk stratificationCommon arrhythmiaNovel anticoagulantsSuccessful therapyWarfarinPatientsGreater mortalityPreventionFibrillationAF researchEffective alternativeNew optionsAnticoagulationImproved management strategiesProphylaxisAnticoagulantsArrhythmiasTherapyMajor progress